BONE BIOLOGICS CORP (BBLG)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.57+1.86%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BBLG
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
BBLG — capital allocation — Unregistered
Dated 2026-07-09
Unregistered Sales of Equity Securities. To the extent required by
Why it matters: Updates can show how well the clinical program is doing and its future.
Supportive ifThe company shares updates on the NB1 pilot study. Patient enrollment is moving forward.
Worry ifThe company does not share updates during the enrollment period.
Why it matters: News on money management will show if the company can keep running until Q2 2027.
Watch forGood news on money management and spending.
Also watch forBad news showing cash flow problems or need for more funding.
Why it matters: If the healthcare sector's revenue growth speeds up, it could help BONE BIOLOGICS. This could improve investor confidence.
Supportive ifHealthcare sector revenue growth is speeding up again. It may reach 9% or more.
Worry ifHealthcare sector revenue growth continues to slow below 9%.
Why it matters: Using the warrants could give more funding for clinical trials and operations.
Supportive ifA significant number of Series F and G warrants are exercised within the next 18 months.
Worry ifFew or no warrants are used, which limits extra funding.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$200 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $704 loss on $10,000 · 7.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,027 loss on $10,000 · 80.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Worsening losses could signal deeper issues in managing costs and cash flow.
Worry ifOperating losses exceed -$805 million in the next quarter.
Less concerning ifOperating losses drop to less than -$805 million.
Why it matters: New money can help operations. It shows that management cares about funding.
Supportive ifManagement says there will be a new equity offering or warrant issuance.
Worry ifNo new capital raises are announced in the next quarter.
Why it matters: Results will show if Bone Biologics keeps its money in check and extends its runway.
Worry ifQ3 results show smaller operating losses than in earlier quarters.
Less concerning ifOperating losses grow or stay high in Q3 results.
Why it matters: Completing enrollment is key for growth and shows progress in management's plans.
Supportive ifManagement says the pilot study enrollment is done by year-end.
Worry ifEnrollment is delayed or not completed by year-end.
Why it matters: Completing enrollment signals progress in the clinical program for NB1. This is key for future trials and product development.
Supportive ifPatient enrollment in the NB1 pilot study is completed by year-end 2026.
Worry ifEnrollment is delayed beyond year-end 2026.
Why it matters: Better product stability can help with manufacturing and supply chain. This is important for future studies.
Supportive ifAn announcement of further extension of rhNELL-1's shelf life beyond 29 months.
Worry ifThere are no updates on product stability. There are no negative findings about shelf life.